Full-Time

Director – Account Management

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$170k - $210kAnnually

+ Annual Bonus + Equity

Senior, Expert

Los Angeles, CA, USA

Category
Strategic Account Management
Sales & Account Management

You match the following Axsome Therapeutics Inc's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor's degree in business, marketing, economics, or health sciences
  • Minimum of 6 years of successful Payer Account Management experience required
  • Strong understanding of the payer landscape and how payer decision making impacts providers and their patients
  • Demonstrated experience gaining formulary access for a launch product at regional payer and PBM accounts
Responsibilities
  • Ensure disciplined and effective communication with key payer stakeholders and decision makers
  • Understand dynamics of Payer (PBM and Plan) relationships, and key decision makers
  • Network across the industry and each account
  • Execute the payer engagement strategy and leverage Payer Value Proposition to obtain appropriate access/formulary position among target accounts
  • Profile key payer accounts to assess formulary review process, formulary coverage policies, utilization management deployed for the applicable therapeutic areas, and geographic coverage areas
  • Identify and address potential barriers to access proactively to ensure launch product is well positioned for formulary and P&T reviews
  • Identify competitive threats and develop strategies to ensure optimal coverage for Axsome Therapeutics’ portfolio of products
  • Lead pull-though initiatives that capitalize on formulary wins and lead push-though efforts in areas with access challenges
  • Ensure compliance with Axsome Therapeutics’ corporate policies and procedures and U.S. healthcare laws and regulations
Desired Qualifications
  • Negotiation experience, preferably in competitive primary care therapeutic areas
  • Analytical mindset and history of leveraging HEOR data to articulate a value story that ensures rapid formulary coverage of launch products
  • A problem-solving mindset with demonstrated “lean-forward” approach and ability to think critically
  • Previous product launch experience, preferably in the CNS space
  • Familiarity with current legal and regulatory landscape pertinent to the industry
  • Previous experience at a small biopharmaceutical company
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
  • Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
  • Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

What critics are saying

  • Increased competition from companies like Compass Pathways in the CNS market.
  • Potential delays in AXS-07 launch amid growing market anticipation.
  • Departure of key personnel like Lori Englebert may impact strategic direction.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders with limited current treatment options.
  • AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity